


FIG. 1

2012220 12299001



**FIG. 2**

3 / 36





FIG. 3

201220-2299001

4 / 36

FIG. 4



5 / 36





FIG. 5

10086217 022402

6 / 36



\*p<0.05 VERSUS NO TREATMENT


FIG. 6

201220 21298001




**FIG. 7**

FIG. 8





9 / 36



10 / 36




FIG. 10

201220" 21298001

11 / 36




FIG. 11

12 / 36






FIG.12

FIG. 13



201220" 129800T



201230 7129300

15 / 36

FIG. 15





FIG. 16





17 / 36

FIG. 17A




FIG. 17B





FIG. 17C



DISEASE FREE


UNTREATED CONTROL

PS/2 TREATED

RAT IgG2b TREATED CONTROL

10086217 022102

FIG. 18




2012220" 1299001


201220" / 1299001

19 / 36

1 ( 200 MICROGRAM ) PS/2 TREATMENT / 1DAY N=3 / GROUP



2 ( 200 MICROGRAM ) PS/2 TREATMENTS / 2DAYS N=3 / GROUP



6 ( 200 MICROGRAM ) PS/2 TREATMENTS / 6DAYS N=5 / GROUP




FIG. 19

20 / 36







FIG. 21



22 / 36

FIG. 22



10066217 022402

23 / 36






FIG. 24





25 / 36



201220" / 1298001

26 / 36

FIG. 26A




FIG. 26B





FIG. 26C



201220 / 2298001

27 / 36

FIG. 27A




FIG. 27B





FIG. 28

	DAY 20	DAY27
	PS/2 PLASMA LEVELS	PS/2 PLASMA LEVELS
8-PS/2	NONE DETECETED	NONE DECTECTED
9-P2/2	NONE DETECTED	NONE DETECTED
10-PS/2	NONE DETECTED	NONE DETECTED
11-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED
12-MELPHALAN+PS/2	3.7 µg/ml	NONE DETECTED
13-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED

201220" / 1298007

FIG. 29



5TGM1 CELLS (1E6) INJECTED (I.V.) ON DAY 0  
 EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20


GROUPS N=2/GROUP

- DISEASE FREE CONTROL
- UNTREATED MYELOMA CONTROL
- PS/2--100 MICROGRAMS/INJECTION
- Sm.Mol. 8809--3mg/kg, 0.3 mg/kg OR 0.03 mg/kg
- Sm.Mol. 9257 CONTROL--3 mg/kg

PERCENTAGE GFP +  
MYELOMA CELLS



PERCENTAGE GFP +  
MYELOMA CELLS



**FIG. 30C**

PERCENTAGE GFP +  
MYELOMA CELLS


[illegible]

FIG. 31A

31 / 36




FIG. 31B






FIG. 31C



20130720 17:03:40

FIG.32



5TGM1 CELLS (1E6) INJECTED (I.V.) ON DAY 0  
PS/2 WAS GIVEN ON DAYS 15,16,17,18,19 AND 20  
SMALL MOLECULE WAS GIVEN ON DAYS 15,16 AND 17  
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 21

GROUPS N=2/GROUP  
DISEASE FREE CONTROL  
UNTREATED MYELOMA CONTROL  
PS/2--100 MICROGRAMS/INJECTION  
8809--3mg/kg, 0.3 mg/kg OR 0.03 mg/kg  
9257 CONTROL--3 mg/kg



FIG. 33A

33 / 36




FIG. 33B





FIG. 33C



201220171298001

34 / 36

FIG. 34A






FIG. 34B



201220 41298001

35 / 36

FIG. 35



36 / 36

FIG. 36

